An interventional study of Prescription for Action (SPHERES Model) in Pregnancy, Neonatal Mortality and Tuberculosis, sponsored by Oxford University Clinical Research Unit Indonesia. Not yet recruiting at 2 sites in Indonesia. Per ClinicalTrials.gov, last updated 2025-08-15.
Sponsored by Oxford University Clinical Research Unit Indonesia · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Tuberculosis with a site in Indonesia — 8 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis · Indonesia.
Among the 38 studies in Tuberculosis with a site in Indonesia, this one has the largest planned enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2025, is one of 18 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 30th registered.
1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.
Browse Tuberculosis studies →8 of the 38 studies in Tuberculosis with a site in Indonesia are open now. Recruiting first, the newest first:
PT Bio Farma · Sites in Indonesia
Ages 18–40 · Healthy volunteers
Universitas Padjadjaran · Sites in Indonesia
Ages 29 days+
National University Hospital, Singapore · Sites in Indonesia, Malaysia, Singapore
Ages 21+
Johns Hopkins University · Sites in Indonesia, India, Mozambique and 4 more countries
Ages 0 days–9 yrs
Universitas Padjadjaran · Sites in Indonesia
Ages 18–55 · Women only
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 8 · Phase 4 1
First in 2006; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,750,000 is above the median of 150 across 822 interventional studies indexed under Tuberculosis.
Median enrollment 78 across the 35 interventional studies, 50 across the 3 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 38 have an industry lead sponsor. The 10 most frequent:
Oxford University Clinical Research Unit Indonesia is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Oxford University Clinical Research Unit Indonesia has 1 study filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Tuberculosis with a site in Indonesia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06253715Phase 3Johns Hopkins UniversityShortened Regimen for Drug-susceptible TB in Children | 2027-09-30 |
| NCT07703696Universitas DiponegoroEffectiveness of Psychosocial Counseling in Patients With a New Tuberculosis Diagnosis | 2026-11-30 |
| NCT07126041Oxford University Clinical Research Unit IndonesiaScalable Public Health Empowerment, Research, and Education Sites (SPHERES) | 2026-12-31 |
| NCT07293455Universitas PadjadjaranEvaluation and Demonstration of New Tuberculosis Diagnostics for Indonesia | 2027-03-31 |
| NCT07647107PT Bio FarmaA Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 38 studies in Tuberculosis with a site in Indonesia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SPHERES is a health service research trial in the Indonesian primary care system designed to improve health system performance using a structured data-driven action model. The intervention empowers district health leaders to make data-informed decisions that will enhance outcomes across maternal, child, infectious, and non-communicable disease programs.
The SPHERES (Scalable Public Health Empowerment, Research and Education Sites) study is a stepped-wedge health service research trial designed to assess the impact of a complex intervention to enhance the performance of Indonesia's primary health care system through an integrated package of digital health tools to enhance data interoperability, human resource and performance improvement, data-driven decision-making, and changes in work culture toward information-based decision-making, actions, and accountability. The central innovation lies in the "prescription for action" approach, wherein district health managers and heads of primary healthcare centers (PHC) create structured monthly prescriptions that describe actions to be taken to improve primary health care informed by real-time health data visualized on interactive dashboards. These prescriptions are tailored to address gap in priority service delivery challenges including gaps in preventive and promotive care - such as low coverage or quality of antenatal, intrapartum, or postnatal care, or missed opportunities for hepatitis B prevention in pregnancy, or gaps in overall diagnosis and treatment of tuberculosis, or gaps in overall screening and diagnosis and treatment of hypertension or diabetes, - and are grounded in both epidemiological insight and health systems analysis.
As a cluster-randomized stepped-wedge health service trial in the Indonesian primary care system, SPHERES involve multiple primary healthcare centers (PHCs) as the unit of intervention across two districts: West Lombok (West Nusa Tenggara Province) and Purbalingga (Central Java Province). At regular intervals (approximately every 4 months), new clusters (approximately 25% of the total number of PHCs in the district) are transitioned from control to intervention status, until all sites receive the SPHERES intervention within 16 months. This phased approach allows for rigorous evaluation while ensuring equitable access to the program. The intervention package includes: (1) establishment of Public Health Data Theaters as training centers for the active use of data for decision-making using interactive dynamic dashboards, public health data rounds, prescriptions for action for precision public health, digital report cards, and team-based care, (2) deployment of Sustainable Scaling Teams to engage districts in developing the essential technical and management skills for digital ecosystems, and (3) establish ecosystems of interoperable data at the district level to support curative, preventive, and promotive care delivery by frontline health workers. Thus, the intervention will be implemented over 16 months, with approximately 25% of PHCs transitioning every quarter from control to intervention in monthly waves, starting August 2025, with all PHCs receiving the intervention by August 2026.
To support high-fidelity implementation, at each phase of the stepped-wedge, each cluster undergoes a two-phase transformation, a pre-intervention digital readiness phase, followed by the intervention interventions, i.e. the "prescriptions for action" phase. The preparatory step focuses on strengthening digital infrastructure and practices at the PHC level, including standardizing electronic health record inputs, and ensuring interoperability across digital health platforms. Sequencing this digitalization phase ahead of the "prescriptions for action" phase enhances the fidelity and compliance for managerial and behavioral actions that may be included within the "prescriptions for action" intervention.
SPHERES targets improvements in coverage, quality, and outcomes across three priority domains: maternal and child health (including immunization and stunting), infectious disease (tuberculosis and hepatitis B), and non-communicable diseases (diabetes and hypertension). The study will assess impacts on service uptake (e.g., ANC 6 coverage, quality of care, diabetes screening), clinical outcomes (e.g., neonatal mortality, TB treatment success, Hepatitis B vertical transmission), and system-level indicators (e.g., prescription compliance, data use in decision-making). Embedded within the project is a robust capacity-building component for health workers and program managers, along with qualitative assessments of acceptability, feasibility, and perceived value.
SPHERES is expected to produce evidence for improving PHC service quality and responsiveness across Indonesia. By combining routine data analytics with a structured decision-support mechanism, the intervention aims to institutionalize active data use at the district level. Findings from SPHERES are expected to inform Indonesia's Ministry of Health Digital Roadmap and broader digital health transformation strategy and offer generalizable insights into how data empowerment combined with human resource management and change in work culture can drive system-wide improvements in low- and middle-income countries.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants (district populations) receive services improved by the SPHERES model, which includes structured prescription-for-action protocols targeting three priority domains (infectious disease, maternal \& child health, and non-communicable diseases).
Other: Prescription for Action (SPHERES Model)
Standard of care are expected at primary health centers before the SPHERES intervention is deployed
A system-level intervention consisting of: * a digital dashboard displaying local health services, outcome indicators, and operational data in a secure Public Health Data Theater; * structured monthly prescription guides targeting service improvements across three priority program areas; * monthly performance monitoring with district health leaders. The intervention is applied at the PHC level, all supported by digital capacity building, district-level deployment of implementation teams, and intersectoral secure health data exchange.
Difference in neonatal mortality rate between intervention and control periods
Neonatal mortality per 1,000 live births, calculated using health facility and civil registration data, and community household sampling surveys
Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)
Difference in complete antenatal care (ANC 6) visit coverage between intervention and control periods
Percentage of pregnant women completing ≥6 ANC visits calculated using health facility data, paper based registry, and/or community household sampling surveys
Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)
Difference in complete basic childhood immunization coverage between the intervention and control period
Proportion of children aged 12-23 months receiving all recommended basic childhood vaccines according to Indonesian Pediatric Society guidelines using health facility data, paper based registry, and/or community household sampling surveys
Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)
Difference in TB treatment success rate between intervention and control periods
Percentage of new bacteriologically confirmed TB patients with documented treatment success (cure or completion) calculated using health facility data
Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)
Difference in screening coverage for diabetes mellitus among adults between the intervention and control periods
Proportion of adults aged ≥40 screened for random blood glucose or fasting blood glucose calculated using health facility data
Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)
Difference in the rate of vertical transmission of hepatitis B between intervention and control periods
Proportion of infants born to hepatitis B surface antigen (HBsAg)-positive mothers who test positive for HBsAg at 9 to 12 months of age. Data will be collected to evaluate the effectiveness of Tenofovir initiation, timely birth dose, routine childhood Hepatitis B vaccination, and HBIG administration as part of the vertical transmission prevention protocol.
Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)
Difference in the uptake of dashboard use among district health managers and heads of PHC
Proportion of monthly coordination meetings in which district health managers and heads of PHC accessed and used the SPHERES digital dashboard to review performance data and guide decision-making. Usage will be measured through system access logs and meeting documentation.
Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)
Difference in prescription-for-action implementation rate at the PHC
Proportion of prescriptions-for-action issued during Public Health Data Theater sessions that are completed by PHCs within one month. Data will be collected from district monitoring reports and PHC-level follow-up documentation.
Time frame: Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)
Plan to share: No — The study will not share individual participant data due to the population-level nature of the intervention and national data privacy regulations. Only aggregated and de-identified/anonymized data and codebook may be made publicly available upon publication. All data collection, storage, and analysis procedures will comply with Indonesia's Personal Data Protection Law (UU PDP), Ministry of Health guidance, and institutional ethical standards.
Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.
Of 169 non-industry interventional studies with no phase under Tuberculosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's planned 16 months is below that.
Counting every sponsor, half of 171 studies reached it within 25 months; a quarter within 14 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oxford University Clinical Research Unit Indonesia